Skip to main content

Table 1 Clinical trials of sorafenib for AML therapy

From: FLT3 inhibitors in acute myeloid leukemia

Study agents

Other agents

Disease

No Pts

Response

Reference

Sorafenib

Decitabine

Relapsed

Refractory

6

OR 83%

CR 80%

[17]

Sorafenib

5-azacytidine

Relapsed

43

OR 46%

[18]

Sorafenib

Daunorubicin

Cytarabine

Untreated

54

1-year OS 62%

DFS 12.2 months

OS 15 months

[20]

Sorafenib

Daunorubicin

Cytarabine

Untreated

267

EFS 21 months

3-year EFS 40%

[21]

  1. OR overall response, CR complete remission, OS overall survival, DFS disease-free survival, EFS event-free survival